Literature DB >> 17469680

Alternatives to placebo-controlled trials.

David L Streiner1.   

Abstract

Until recently, the gold standard for assessing the efficacy and effectiveness of new medications has been the placebo-control randomized clinical trial (RCT). However, there are serious ethical concerns about placing patients on a placebo when effective treatments exist. Further, if a new agent is tested only against a placebo, there is no guarantee that it is more effective, or even as effective, as an existing agent. For these and other reasons, ethicists and regulatory bodies have said that, under these circumstances, new drugs should be tested against an active agent. There are three types of such trials: superiority, equivalence, and non-inferiority. In superiority trials, the goal is to establish that the new drug is better (i.e., more effective, or with a more benign side-effect profile) than the standard. Because such trials require much larger sample sizes than placebo-control studies, and are rarely required to bring a drug onto market, they are rarely done. In equivalence trials, the aim is to show that the new and standard agents have similar degrees of effectiveness or adverse events. Due to sample size requirements, most studies of new drugs are non-inferiority trials, in which it is sufficient to demonstrate that the new drug is not significantly worse than the existing ones. However, there are methodological concerns with equivalence and non-inferiority trials, including (a) an inability to determine if the drugs were equally good or equally bad; (b) poorly executed trials with low power can be mistaken for "proving" equivalence or non-inferiority; (c) the equivalence interval is arbitrary; (d) successive non-inferiority trials may lead to a gradual reduction in effectiveness; and (e) often larger trials are necessary. The paper also discusses "add on trials." It is recommended that, even when existing drugs exist, trials should consist of at least three arms, one of which is a placebo. This paper briefly considers the ethics of placebo, and conditions are stated under which such studies can be conducted.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17469680     DOI: 10.1017/s0317167100005540

Source DB:  PubMed          Journal:  Can J Neurol Sci        ISSN: 0317-1671            Impact factor:   2.104


  10 in total

1.  Early human screening of medications to treat drug addiction: novel paradigms and the relevance of pharmacogenetics.

Authors:  K A Perkins; C Lerman
Journal:  Clin Pharmacol Ther       Date:  2011-01-26       Impact factor: 6.875

2.  Feasibility of reducing the duration of placebo-controlled trials in schizophrenia research.

Authors:  Robert P McMahon; Deanna L Kelly; Douglas L Boggs; Lan Li; Qiaoyan Hu; John M Davis; William T Carpenter
Journal:  Schizophr Bull       Date:  2008-01-08       Impact factor: 9.306

Review 3.  Rationale for and methods of superiority, noninferiority, or equivalence designs in orthopaedic, controlled trials.

Authors:  Patrick Vavken
Journal:  Clin Orthop Relat Res       Date:  2011-01-19       Impact factor: 4.176

4.  Use of Placebo in Clinical Trials of Psychotropic Medication.

Authors:  Mehrul Hasnain; Abraham Rudnick; Weldon S Bonnell; Gary Remington; Raymond W Lam
Journal:  Can J Psychiatry       Date:  2018-05       Impact factor: 4.356

Review 5.  An efficient early phase 2 procedure to screen medications for efficacy in smoking cessation.

Authors:  Kenneth A Perkins; Caryn Lerman
Journal:  Psychopharmacology (Berl)       Date:  2013-12-03       Impact factor: 4.530

6.  Sensitivity and specificity of a procedure for early human screening of novel smoking cessation medications.

Authors:  Kenneth A Perkins; Caryn Lerman; Joshua L Karelitz; Nancy C Jao; K N Roy Chengappa; Garrett M Sparks
Journal:  Addiction       Date:  2013-07-12       Impact factor: 6.526

7.  Antipsychotic agents: efficacy and safety in schizophrenia.

Authors:  Arão Nogueira de Araújo; Eduardo Pondé de Sena; Irismar Reis de Oliveira; Mario F Juruena
Journal:  Drug Healthc Patient Saf       Date:  2012-11-29

Review 8.  The clinical investigator-subject relationship: a contextual approach.

Authors:  David B Resnik
Journal:  Philos Ethics Humanit Med       Date:  2009-12-03       Impact factor: 2.464

9.  Video-assisted thoracic surgery (VATS) as a safe alternative for the resection of pulmonary metastases: a retrospective cohort study.

Authors:  Marilee Carballo; Mary S Maish; Dawn E Jaroszewski; Carmack E Holmes
Journal:  J Cardiothorac Surg       Date:  2009-02-24       Impact factor: 1.637

Review 10.  Treatment comparison in rheumatoid arthritis: head-to-head trials and innovative study designs.

Authors:  Ennio Giulio Favalli; Serena Bugatti; Martina Biggioggero; Roberto Caporali
Journal:  Biomed Res Int       Date:  2014-04-16       Impact factor: 3.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.